학술논문
ABCL-023 frontMIND: A Phase III, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
Document Type
Article
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S352-S353
Subject
Language
ISSN
2152-2650